IBA, Fred Hutchinson Cancer Center and the University of Washington engage in a bench-to-bedside research program for FLASH Proton Therapy
02 Août 2022 - 7:00AM
IBA, Fred Hutchinson Cancer Center and the University of Washington
engage in a bench-to-bedside research program for FLASH Proton
Therapy
Louvain-la-Neuve, Belgium, August 2,
2022, IBA (Ion Beam Applications S.A., EURONEXT), the
world leader in particle accelerator technology, Fred Hutchinson
Cancer Center and the University of Washington (UW), Seattle,
announced a multi-year research collaboration today on
ConformalFLASH®1 Proton Therapy. Under this collaboration, IBA will
equip the proton therapy system and the proton gantry treatment
room at the Fred Hutchinson Cancer Center with ConformalFLASH®
research functionality, which will enable preclinical research on
FLASH therapy. In the future this could lead to a new clinical
functionality for patients.
Radiation therapy has advanced drastically in
the last few decades because of continued technological innovation,
allowing for safer and more accurate methods to treat a
comprehensive range of solid tumors. FLASH radiation, defined as
the delivery of radiation at ultra-high dose rates (40-60Gy/s), has
been shown to spare to normal tissue toxicity while maintaining an
equivalent anti-tumor efficacy2,3. FLASH is expected to
dramatically change the landscape of radiotherapy and patient
cancer care by enhancing the therapeutic window with less toxicity,
allowing shorter treatment times and potential for dose escalation
on radioresistant tumors for improved tumor control. IBA's
ConformalFLASH® approach combines the biological sparing effects of
FLASH with the use of the spatial selectivity of the Proton Bragg
peak.
As part of this collaboration, UW School of
Medicine scientists will lead a comprehensive bench-to-bedside
program at the Fred Hutchinson Cancer Center to analyze
FLASH‐Radiotherapy (FLASH-RT) in pre‐clinical models to optimally
deployed FLASH-RT for cancer patients. The focus would be to
evaluate the optimal physical parameters for proton FLASH
irradiation, including Pencil Beam Scanning (PBS) FLASH dose rates
and FLASH effects in the Spread-Out Bragg Peak (SOBP).
Swati Girdhani, Director, Research
Collaborations at IBA, said: “In the last few years, IBA
has been working closely with customers to support innovation,
leading to breakthrough technologies like ConformalFLASH®. In this
era of value-centered medicine, ConformalFLASH® has the potential
to advance radiotherapy towards increased use of
ultra-hypofractionation while significantly improving the
therapeutic index. We are delighted to be working with the
University of Washington, one of the leading centers for research
in the United States to bring ConformalFLASH® technology to
patients.”
*** Ends ***
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 1,600 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
For further information, please
contact:
IBA
Nicolas DenefGlobal Marketing
Directorglobal.marketing@iba-group.com
Olivier LechienCorporate
Communication Director+32 10 475 890communication@iba-group.com
For media and investor enquiries: Consilium
Strategic Communications Amber Fennell, Angela Gray, Lucy
Featherstone +44 (0) 20 3709 5700 IBA@consilium-comms.com
1 ConformalFLASH® is a registered brand of IBA’s Proton FLASH
irradiation solution currently under research and development
phase.
2 Diffenderfer et al IJROBP 2020 “Design, Implementation, and in
Vivo Validation of a Novel Proton FLASH Radiation Therapy
System”.
3 Velalopoulou et al Cancer Research 2021 “FLASH Proton
Radiotherapy Spares Normal Epithelial and Mesenchymal Tissues While
Preserving Sarcoma Response”.
- 220802__University-Washington_IBA_FLASH_EN-b
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024